Your browser is no longer supported. Please, upgrade your browser.
INCY [NASD]
Incyte Corporation
IndexS&P 500 P/E31.01 EPS (ttm)2.42 Insider Own0.40% Shs Outstand220.84M Perf Week2.31%
Market Cap16.27B Forward P/E17.36 EPS next Y4.31 Insider Trans177.33% Shs Float217.49M Perf Month4.01%
Income534.60M PEG2.07 EPS next Q0.86 Inst Own94.80% Short Float1.41% Perf Quarter14.22%
Sales2.91B P/S5.58 EPS this Y-166.00% Inst Trans1.08% Short Ratio1.37 Perf Half Y-3.46%
Book/sh14.26 P/B5.25 EPS next Y23.12% ROA14.00% Target Price92.38 Perf Year-17.31%
Cash/sh10.51 P/C7.12 EPS next 5Y15.00% ROE18.70% 52W Range61.91 - 101.47 Perf YTD2.02%
Dividend- P/FCF29.93 EPS past 5Y33.32% ROI-12.40% 52W High-26.20% Beta0.72
Dividend %- Quick Ratio3.90 Sales past 5Y28.80% Gross Margin95.80% 52W Low20.95% ATR2.02
Employees1773 Current Ratio3.90 Sales Q/Q31.00% Oper. Margin21.90% RSI (14)61.28 Volatility2.42% 2.52%
OptionableYes Debt/Eq0.01 EPS Q/Q- Profit Margin18.40% Rel Volume0.69 Prev Close73.65
ShortableYes LT Debt/Eq0.01 EarningsNov 02 BMO Payout0.00% Avg Volume2.23M Price74.88
Recom2.10 SMA202.17% SMA508.22% SMA200-0.76% Volume1,541,052 Change1.67%
Nov-19-21Initiated BMO Capital Markets Market Perform $75
Jul-20-21Upgrade The Benchmark Company Hold → Buy $89
Feb-10-21Downgrade SVB Leerink Mkt Perform → Underperform $70
Jan-07-21Initiated Truist Buy $120
Jan-04-21Upgrade Guggenheim Neutral → Buy
Jun-16-20Initiated The Benchmark Company Hold
May-06-20Downgrade JP Morgan Overweight → Neutral $89 → $99
Apr-29-20Downgrade Morgan Stanley Overweight → Equal-Weight $94
Apr-01-20Upgrade Morgan Stanley Equal-Weight → Overweight $83 → $90
Mar-24-20Resumed William Blair Outperform
Mar-13-20Upgrade BofA/Merrill Neutral → Buy $83
Feb-04-20Resumed BofA/Merrill Neutral $82
Jan-03-20Reiterated BMO Capital Markets Market Perform $85 → $74
Jan-03-20Downgrade Mizuho Buy → Neutral $98 → $79
Jan-02-20Downgrade Guggenheim Buy → Neutral
Oct-03-19Initiated Mizuho Buy $95
Sep-12-19Initiated BMO Capital Markets Market Perform
Sep-05-19Upgrade Oppenheimer Perform → Outperform $100
Sep-05-19Upgrade JMP Securities Mkt Perform → Mkt Outperform $107
Sep-05-19Resumed Morgan Stanley Equal-Weight $82 → $87
Jan-06-22 05:38PM  
Dec-16-21 08:36AM  
Dec-15-21 09:06AM  
Dec-14-21 04:30PM  
08:00AM  
Dec-13-21 08:45PM  
12:55PM  
Dec-11-21 12:00PM  
09:00AM  
Dec-08-21 07:38PM  
03:34PM  
Dec-06-21 10:04AM  
Dec-02-21 11:31AM  
Nov-09-21 08:30AM  
08:00AM  
Nov-04-21 10:07AM  
09:00AM  
Nov-02-21 12:00PM  
09:24AM  
08:50AM  
08:35AM  
07:00AM  
06:34AM  
Nov-01-21 09:16AM  
07:00AM  
Oct-29-21 09:48AM  
Oct-28-21 10:33AM  
07:47AM  
Oct-27-21 10:14AM  
10:00AM  
10:00AM  
Oct-26-21 03:02PM  
12:10PM  
Oct-22-21 09:26AM  
Oct-21-21 06:40AM  
Oct-20-21 01:23PM  
Oct-13-21 10:29AM  
09:12AM  
08:00AM  
Oct-12-21 10:57AM  
Oct-02-21 05:15AM  
Sep-30-21 05:56AM  
Sep-29-21 10:47AM  
Sep-28-21 05:00PM  
12:15PM  
Sep-27-21 09:23AM  
06:00AM  
Sep-23-21 11:08AM  
09:15AM  
08:19AM  
07:30AM  
Sep-22-21 01:54PM  
12:38PM  
11:36AM  
08:59AM  
08:36AM  
08:29AM  
07:45AM  
Sep-21-21 04:13PM  
Sep-20-21 01:46PM  
Sep-17-21 04:00PM  
Sep-13-21 04:30PM  
Sep-02-21 11:31AM  
08:34AM  
Sep-01-21 10:44AM  
Aug-27-21 11:09AM  
06:19AM  
Aug-26-21 04:01PM  
Aug-24-21 08:30AM  
Aug-19-21 10:02AM  
Aug-17-21 08:28AM  
08:00AM  
06:37AM  
Aug-16-21 07:00PM  
03:13PM  
Aug-10-21 02:49AM  
Aug-07-21 08:01AM  
Aug-03-21 04:30PM  
12:43PM  
08:25AM  
07:00AM  
06:31AM  
06:00AM  
Aug-02-21 09:36AM  
Jul-31-21 08:38AM  
Jul-28-21 01:51PM  
09:59AM  
Jul-27-21 03:03PM  
Jul-23-21 04:30PM  
Jul-22-21 11:40AM  
Jul-19-21 11:16AM  
10:31AM  
Jul-16-21 01:57PM  
Jul-15-21 08:00AM  
07:56AM  
07:12AM  
Jul-14-21 05:00PM  
Jul-09-21 09:47AM  
Jul-06-21 12:43AM  
Jun-28-21 01:18PM  
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naive chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SWAIN PAULA JEVP, Human ResourcesJan 07Option Exercise73.2110,870795,79383,241Jan 11 04:18 PM
SWAIN PAULA JEVP, Human ResourcesJan 07Sale73.3110,870796,88072,371Jan 11 04:18 PM
SWAIN PAULA JEVP, Human ResourcesJan 04Option Exercise73.219,319682,24481,690Jan 05 04:25 PM
SWAIN PAULA JEVP, Human ResourcesJan 04Sale73.469,319684,57472,371Jan 05 04:25 PM
Trower PaulPrincipal Accounting OfficerJan 03Option Exercise73.218,214601,34739,086Jan 05 04:40 PM
Trower PaulPrincipal Accounting OfficerJan 03Sale73.318,214602,16832,268Jan 05 04:40 PM
DIXON WENDY LDirectorDec 23Option Exercise73.2520,0001,465,00037,259Dec 27 04:11 PM
DIXON WENDY LDirectorDec 23Sale22.0520,000441,00017,259Dec 27 04:11 PM
BAKER BROS. ADVISORS LPDirectorDec 17Buy72.801,075,87278,322,14830,932,696Dec 17 06:30 PM
BAKER BROS. ADVISORS LPDirectorDec 16Buy71.96169,31512,184,41129,856,824Dec 17 06:30 PM
BAKER BROS. ADVISORS LPDirectorDec 15Buy71.51350,33225,052,34029,687,509Dec 17 06:30 PM
Dhanak DashyantEVP & Chief Scientific OfficerOct 01Sale68.6738926,71331,263Oct 04 04:41 PM
Pasquale Maria EEVP & General CounselSep 24Option Exercise65.3638224,96836,187Sep 28 08:18 AM
SWAIN PAULA JEVP, Human ResourcesSep 20Option Exercise73.211,35699,27360,959Sep 21 04:09 PM
Dhanak DashyantEVP & Chief Scientific OfficerSep 01Sale76.7138829,76331,652Sep 03 07:40 AM
Dhanak DashyantEVP & Chief Scientific OfficerAug 02Sale77.4938930,14432,040Aug 04 04:16 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJul 29Sale78.294,911384,48227,005Aug 02 04:14 PM
Wenqing YaoEVP, Head of Discovery ChemJun 29Sale85.3727,1942,321,55294,080Jun 30 04:11 PM
Pasquale Maria EEVP & General CounselJun 18Option Exercise65.3625516,66730,193Jun 22 04:04 PM
Dhanak DashyantEVP & Chief Scientific OfficerJun 10Option Exercise65.423,845251,54030,390Jun 14 04:28 PM
Dhanak DashyantEVP & Chief Scientific OfficerJun 10Sale87.003,845334,51526,545Jun 14 04:28 PM
Dhanak DashyantEVP & Chief Scientific OfficerJun 01Sale84.1339533,23126,545Jun 03 04:42 PM
BAKER BROS. ADVISORS LPDirectorMay 14Option Exercise18.9740,000758,80029,334,516May 18 04:25 PM
Pasquale Maria EEVP & General CounselApr 23Option Exercise65.361278,30129,938Apr 27 04:57 PM
Dhanak DashyantEVP & Chief Scientific OfficerApr 01Sale81.5739632,30227,336Apr 05 04:25 PM
Morrissey Michael JamesEVP, Head of Tech. OperationsMar 29Sale81.0820,0001,621,60045,452Mar 31 04:10 PM
Pasquale Maria EEVP & General CounselMar 12Option Exercise65.361288,36630,328Mar 16 04:17 PM
Dhanak DashyantEVP & Chief Scientific OfficerMar 01Sale79.7339531,49327,732Mar 03 04:28 PM
Hoppenot HerveChairman / CEOFeb 23Buy77.3712,9251,000,007284,231Feb 23 04:54 PM
Pasquale Maria EEVP & General CounselFeb 16Option Exercise65.361278,30130,200Feb 18 04:38 PM
Dhanak DashyantEVP & Chief Scientific OfficerFeb 01Option Exercise65.4296162,86929,483Feb 03 04:27 PM
Dhanak DashyantEVP & Chief Scientific OfficerFeb 01Sale90.001,356122,04028,127Feb 03 04:27 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJan 25Option Exercise72.864,116299,89231,274Jan 27 05:03 PM
Wenqing YaoEVP, Head of Discovery ChemJan 25Option Exercise73.2121,5451,577,309163,770Jan 27 05:32 PM
Stein Steven HEVP & Chief Medical OfficerJan 25Option Exercise68.623,795260,413123,539Jan 27 05:09 PM
Wenqing YaoEVP, Head of Discovery ChemJan 25Sale100.0021,5452,154,500143,784Jan 27 05:32 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJan 25Sale99.005,116506,48426,158Jan 27 05:03 PM
Stein Steven HEVP & Chief Medical OfficerJan 25Sale100.003,795379,500119,744Jan 27 05:09 PM
Flannelly Barry PEVP & General Manager USJan 25Sale100.002,744274,40049,994Jan 27 04:52 PM